What is the 13F Pro Quality Score for AVIR?

13F Pro ranks Atea Pharmaceuticals, Inc. (AVIR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AVIR's current score at https://13fpro.ai/research/AVIR (free sign-up required for the full ranking).

Which hedge funds own the most AVIR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AVIR include FMR, BlackRock,, BML Capital Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AVIR as soon as new 13F filings post.

Where does 13F Pro source AVIR data?

All Atea Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Atea Pharmaceuticals, Inc. files with the SEC under CIK 1593899. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AVIR in?

Atea Pharmaceuticals, Inc. (AVIR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AVIR research updated on 13F Pro?

AVIR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Atea Pharmaceuticals, Inc.(AVIR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1593899 AVIR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

AVIR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Atea Pharmaceuticals, Inc. (AVIR), a Healthcare sector company. AVIR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Atea Pharmaceuticals, Inc. reports net income of $-45.4M, free cash flow of $-46.4M. Top institutional holders of AVIR by reported 13-F value include FMR, BlackRock,, BML Capital Management,, based on the most recent SEC filings. AVIR trades on the Nasdaq exchange and files with the SEC under CIK 1593899. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVIR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Atea Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-45.4M

Free Cash Flow

Q1 2026

$-46.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY20 $48.6MFY21 $351.4MFY23 —FY25 —

Net Income

-16.5% YoY

$-158.3MFY 2025

FY20 $-10.9MFY21 $121.2MFY23 $-136.0MFY25 $-158.3M

Operating Income

-10.2% YoY

$-180.9MFY 2025

FY20 $-11.0MFY21 $138.4MFY23 $-164.2MFY25 $-180.9M

EPS (Diluted)

-19.0% YoY

$-1.94FY 2025

FY20 $-0.51FY21 $1.37FY23 $-1.63FY25 $-1.94

Total Assets

-47.0% YoY

$315.2MFY 2025

FY20 $863.6MFY21 $772.9MFY23 $595.0MFY25 $315.2M

Op. Cash Flow

-54.6% YoY

$-132.0MFY 2025

FY20 $296.7MFY21 $-87.0MFY23 $-85.4MFY25 $-132.0M

Metric	FY 2025	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	—	—	$351.4M +622.5%	$48.6M	—	—
Net Income	$-158.3M -16.5%	$-136.0M -212.2%	$121.2M +1207.1%	$-10.9M +22.0%	$-14.0M -54.8%	$-9.1M
Operating Income	$-180.9M -10.2%	$-164.2M -218.6%	$138.4M +1354.6%	$-11.0M +24.5%	$-14.6M -54.1%	$-9.5M
EPS (Diluted)	$-1.94 -19.0%	$-1.63 -219.0%	$1.37 +368.6%	$-0.51 +63.3%	$-1.39	—
Total Assets	$315.2M -47.0%	$595.0M -23.0%	$772.9M -10.5%	$863.6M +3812.6%	$22.1M	—
Operating Cash Flow	$-132.0M -54.6%	$-85.4M +1.9%	$-87.0M -129.3%	$296.7M +2413.0%	$-12.8M -62.2%	$-7.9M

AI Insight: AVIR Financial Trends

Atea is burning cash and equity at an accelerating pace with no visible revenue, shrinking shareholder value by 51% since Q2 2024.

• Operating losses widened from $47M (Q2 2024) to $55M (Q4 2025), then stabilized at $48M (Q1 2026).

• Operating cash outflow deteriorated to $46M in Q1 2026, worst quarter in 8-quarter span.

• Equity halved from $476M (Q2 2024) to $234M (Q1 2026); no debt disclosure suggests cash depletion via operations.

⚠ No revenue reported across all eight quarters; cash runway at current burn (~$46M/quarter) now ~5 quarters.

⚠ Net losses accelerated Q4 2025–Q1 2026 to $45M/quarter, offset only by slowing operating cash burn in Q4 2025.

AI Insight: AVIR Ratio Trends

Atea's returns have deteriorated sharply across all metrics—ROE, ROA, and ROIC all worsening materially since Q2 2024, with Q1 2026 marking the lowest point in the dataset.

• ROE collapsed from -34.0% in Q2 2024 to -77.8% in Q1 2026; ROIC declined from -39.4% to -82.2% over same period.

• Deterioration accelerated in recent quarters: ROA fell from -38.0% in Q2 2025 to -68.1% in Q1 2026.

⚠ Negative returns across all profitability and efficiency metrics indicate persistent unprofitability; trajectory worsening, not improving.

⚠ TTM ROIC at -81.2% signals cumulative 12-month value destruction; urgent need to return to profitability.

Get alerted when AVIR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Atea Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AVIR

FMR LLC
$64.3M11,950,772 sh
BlackRock, Inc.
$45.4M8,435,437 sh
BML Capital Management, LLC
$38.0M7,058,657 sh
TANG CAPITAL MANAGEMENT LLC
$25.9M4,814,700 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.5M3,246,124 sh
Bain Capital Life Sciences Investors, LLC
$12.7M2,360,638 sh
TWO SIGMA INVESTMENTS, LP
$10.0M1,864,164 sh
GEODE CAPITAL MANAGEMENT, LLC
$9.4M1,747,706 sh
STATE STREET CORP
$9.1M1,694,635 sh
DIMENSIONAL FUND ADVISORS LP
$6.8M1,255,484 sh

Fund	Value	Shares
FMR LLC	$64.3M	11,950,772
BlackRock, Inc.	$45.4M	8,435,437
BML Capital Management, LLC	$38.0M	7,058,657
TANG CAPITAL MANAGEMENT LLC	$25.9M	4,814,700
VANGUARD CAPITAL MANAGEMENT LLC	$17.5M	3,246,124
Bain Capital Life Sciences Investors, LLC	$12.7M	2,360,638
TWO SIGMA INVESTMENTS, LP	$10.0M	1,864,164
GEODE CAPITAL MANAGEMENT, LLC	$9.4M	1,747,706
STATE STREET CORP	$9.1M	1,694,635
DIMENSIONAL FUND ADVISORS LP	$6.8M	1,255,484

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AVIR on your watchlist

Track score changes the day Atea Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AVIR a good stock to buy?

13F Pro's AI-powered analysis of Atea Pharmaceuticals, Inc. (AVIR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVIR are available on the AVIR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AVIR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVIR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Atea Pharmaceuticals, Inc.'s investment landscape.